Mediktor Acquires Sensely and Consolidates Its Position as a Leader in AI Healthcare Solutions

BARCELONA, ESP. and SAN FRANCISCO, CA. June 4th 2024 — Mediktor, the leading digital healthcare company, has announced the acquisition of Sensely, a San Francisco-based, digital healthcare provider that pioneered an empathy-driven conversation platform to support hospital systems and insurance services with world-class member engagement. This consolidation of two world-leading artificial intelligence-driven solutions providers marks a major medical technology milestone, extending Mediktor’s global presence to more than 35 countries and expanding its…

HUAV Partners with Mediktor for Improved Urgent Care Management

Hospital Universitario Arnau de Vilanova (HUAV) is a healthcare provider in Lleida, Alto Pirineo y Arán, and parts of La Franja in Aragón, Spain. Healthcare professionals were struggling with overcrowded waiting rooms, and the HUAV was looking for a digital solution to help manage urgent care effectively.  Full article:

Why Your Company Needs an AI Assistant: Patient Engagement from First Contact

In an era where digital transformation is reshaping healthcare, the industry is experiencing a significant shift towards more patient-centered services. AI-based virtual assistance is at the forefront of this transformation, providing seamless, efficient, and personalized guidance at symptom onset. Its role in facilitating patient engagement is becoming increasingly indispensable for every stakeholder in the healthcare ecosystem. You can read the full article here:  

Peptomyc Appoints Selwyn Ho to its Board of Directors

Barcelona, Spain, March 21st, 2024 Peptomyc S.L., a clinical stage company specialized in the development of protein therapeutics targeting the MYC oncoprotein for cancer treatment, today announced the appointment of Dr. Selwyn Ho, MB, BS, to its Board of Directors. Giacomo Di Nepi, Chairman of Peptomyc, says: “We are delighted to have Selwyn joining us. His impressive track record in the Healthcare sector, together with his experience in different executive…

Peptomyc presents results of their Ph1 study of OMO-103 in advanced solid tumours.

OMO-103 is an inhibitor for MYC, one of the most wanted, long-considered, undruggable oncogenes. The trial has established the safety, tolerability and pharmacokinetic profile of OMO-103, advising on Ph2 design and identifying soluble factors with the potential as pharmacodynamic and predictive response markers.